OKYO Pharma Limited
OKYO · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $3 | $4 | $4 | $2 |
| Gross Profit | -$3 | -$4 | -$4 | -$2 |
| % Margin | – | – | – | – |
| R&D Expenses | $2,254 | $8,244 | $6,338 | $1,610 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $4,932 | $7,447 | $6,746 | $4,928 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$6,746 | -$320 |
| Operating Expenses | $7,186 | $15,691 | $6,338 | $6,218 |
| Operating Income | -$7,189 | -$15,695 | -$13,087 | -$6,231 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$781 | -$1,108 | -$197 | $0 |
| Pre-Tax Income | -$7,970 | -$16,803 | -$13,284 | -$6,218 |
| Tax Expense | -$3,264 | $22 | -$12 | -$787 |
| Net Income | -$4,706 | -$16,825 | -$13,272 | -$5,431 |
| % Margin | – | – | – | – |
| EPS | -0.12 | -0.001 | -0.6 | -0.36 |
| % Growth | -19,900% | 99.9% | -66.7% | – |
| EPS Diluted | -0.12 | -0.001 | -0.6 | -0.36 |
| Weighted Avg Shares Out | 39,488 | 29,343 | 22,257 | 15,064 |
| Weighted Avg Shares Out Dil | 39,488 | 29,343 | 22,257 | 15,064 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $0 | $0 | $0 |
| Interest Expense | $884 | $1,053 | $97 | $0 |
| Depreciation & Amortization | $3 | $4 | $4 | $2 |
| EBITDA | -$7,084 | -$15,746 | -$13,183 | -$6,215 |
| % Margin | – | – | – | – |